VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q110687940 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000130.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q110687940‏
035 ‎‡a (OCoLC)Q110687940‏
100 0 ‎‡a John Roberts‏ ‎‡c pharmaceutical researcher at Amgen, Cambridge, USA‏ ‎‡9 en‏
670 ‎‡a Author's Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research‏
670 ‎‡a Author's Application of Transmural Flow Across In Vitro Microvasculature Enables Direct Sampling of Interstitial Therapeutic Molecule Distribution‏
670 ‎‡a Author's Comparison of In Vitro to In Vivo Extrapolation Approaches for Predicting Transporter-Mediated Hepatic Uptake Clearance Using Suspended Rat Hepatocytes‏
670 ‎‡a Author's Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors‏
670 ‎‡a Author's Improved Pharmacokinetics of AMG 517 Through Co-Crystallization Part 1: Comparison of Two Acids With Corresponding Amide Co-crystals‏
670 ‎‡a Author's Improved pharmacokinetics of AMG 517 through co-crystallization part 2: analysis of 12 carboxylic acid co-crystals‏
670 ‎‡a Author's Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7.‏
670 ‎‡a Author's Ratios of biliary glutathione disulfide‏
670 ‎‡a Author's Ratios of biliary glutathione disulfide (GSSG) to glutathione (GSH): a potential index to screen drug-induced hepatic oxidative stress in rats and mice‏
670 ‎‡a Author's Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.‏
670 ‎‡a Author's Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds‏
919 ‎‡a useofuptakeintrinsicclearancefromattachedrathepatocytestopredicthepaticclearanceforpoorlypermeablecompounds‏ ‎‡A Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds‏ ‎‡9 1‏
919 ‎‡a albuminmediateduptakeimproveshumanclearancepredictionforhepaticuptaketransportersubstratesaidingamechanisticinvitroinvivoextrapolationivivestrategyindiscoveryresearch‏ ‎‡A Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research‏ ‎‡9 1‏
919 ‎‡a applicationoftransmuralflowacrossinvitromicrovasculatureenablesdirectsamplingofinterstitialtherapeuticmoleculedistribution‏ ‎‡A Application of Transmural Flow Across In Vitro Microvasculature Enables Direct Sampling of Interstitial Therapeutic Molecule Distribution‏ ‎‡9 1‏
919 ‎‡a comparisonofinvitrotoinvivoextrapolationapproachesforpredictingtransportermediatedhepaticuptakeclearanceusingsuspendedrathepatocytes‏ ‎‡A Comparison of In Vitro to In Vivo Extrapolation Approaches for Predicting Transporter-Mediated Hepatic Uptake Clearance Using Suspended Rat Hepatocytes‏ ‎‡9 1‏
919 ‎‡a discoveryofabiarylamideseriesofpotentstatedependentnav17inhibitors‏ ‎‡A Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors‏ ‎‡9 1‏
919 ‎‡a improvedpharmacokineticsofamg517throughcocrystallizationpart1comparisonof2acidswithcorrespondingamidecocrystals‏ ‎‡A Improved Pharmacokinetics of AMG 517 Through Co-Crystallization Part 1: Comparison of Two Acids With Corresponding Amide Co-crystals‏ ‎‡9 1‏
919 ‎‡a improvedpharmacokineticsofamg517throughcocrystallizationpart2analysisof12carboxylicacidcocrystals‏ ‎‡A Improved pharmacokinetics of AMG 517 through co-crystallization part 2: analysis of 12 carboxylic acid co-crystals‏ ‎‡9 1‏
919 ‎‡a pharmacologiccharacterizationofamg8379apotentandselectivesmallmoleculesulfonamideantagonistofthevoltagegatedsodiumchannelnav17‏ ‎‡A Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7.‏ ‎‡9 1‏
919 ‎‡a ratiosofbiliaryglutathionedisulfide‏ ‎‡A Ratios of biliary glutathione disulfide‏ ‎‡9 1‏
919 ‎‡a ratiosofbiliaryglutathionedisulfidegssgtoglutathionegshapotentialindextoscreendruginducedhepaticoxidativestressinratsandmice‏ ‎‡A Ratios of biliary glutathione disulfide (GSSG) to glutathione (GSH): a potential index to screen drug-induced hepatic oxidative stress in rats and mice‏ ‎‡9 1‏
919 ‎‡a sulfonamidesasselectivenav17inhibitorsoptimizingpotencypharmacokineticsandmetabolicpropertiestoobtainatropisomericquinolinoneam0466thataffordsrobustinvivoactivity‏ ‎‡A Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000400115844‏
996 ‎‡2 ISNI|0000000392680017‏
996 ‎‡2 BNF|18112162‏
996 ‎‡2 CAOONL|ncf13702269‏
996 ‎‡2 RERO|A022775328‏
996 ‎‡2 NII|DA0073198X‏
996 ‎‡2 LC|no2013103721‏
996 ‎‡2 J9U|987007313187405171‏
996 ‎‡2 LC|no2012029402‏
996 ‎‡2 LC|n 96019718‏
996 ‎‡2 NUKAT|n 2013142902‏
996 ‎‡2 BNF|15061037‏
996 ‎‡2 DNB|1038563062‏
996 ‎‡2 LC|no 99017446‏
996 ‎‡2 NII|DA06311794‏
996 ‎‡2 ISNI|0000000074151558‏
996 ‎‡2 BIBSYS|99066888‏
996 ‎‡2 DNB|1016625669‏
996 ‎‡2 LC|no 00041844‏
996 ‎‡2 PLWABN|9810653730205606‏
996 ‎‡2 LC|nb2014020834‏
996 ‎‡2 ISNI|0000000039164249‏
996 ‎‡2 NII|DA03463060‏
996 ‎‡2 BIBSYS|90125853‏
996 ‎‡2 LC|nb2010018671‏
996 ‎‡2 SUDOC|120020580‏
996 ‎‡2 PLWABN|9810603198105606‏
996 ‎‡2 CAOONL|ncf11483486‏
996 ‎‡2 LC|no 98091022‏
996 ‎‡2 ISNI|0000000487183398‏
996 ‎‡2 NII|DA01272039‏
996 ‎‡2 NTA|126705925‏
996 ‎‡2 SUDOC|19022228X‏
996 ‎‡2 J9U|987007332100805171‏
996 ‎‡2 J9U|987007441232005171‏
996 ‎‡2 LC|nr 93033456‏
996 ‎‡2 LC|n 96800146‏
996 ‎‡2 N6I|vtls000694830‏
996 ‎‡2 SUDOC|028444981‏
996 ‎‡2 ISNI|0000000029481611‏
996 ‎‡2 LIH|LNB:C_i_8O;=BZ‏
996 ‎‡2 B2Q|0000121233‏
996 ‎‡2 NLA|000035683664‏
996 ‎‡2 LC|n 79061296‏
996 ‎‡2 ISNI|0000000117536854‏
996 ‎‡2 ISNI|000000003839726X‏
996 ‎‡2 LIH|LNB:V-264934;=BO‏
996 ‎‡2 ISNI|0000000501134833‏
996 ‎‡2 NKC|js20051017056‏
996 ‎‡2 J9U|987007437537005171‏
996 ‎‡2 SUDOC|188264841‏
996 ‎‡2 DNB|133374971‏
996 ‎‡2 LC|n 88623560‏
996 ‎‡2 ISNI|0000000108448502‏
996 ‎‡2 LNB|LNC10-000063945‏
996 ‎‡2 ISNI|0000000047031083‏
996 ‎‡2 NDL|00473866‏
996 ‎‡2 NII|DA07382980‏
996 ‎‡2 NUKAT|n 2016149135‏
996 ‎‡2 NII|DA12700837‏
996 ‎‡2 ISNI|0000000029054628‏
996 ‎‡2 DNB|1046457659‏
996 ‎‡2 LC|n 2023021635‏
996 ‎‡2 LIH|LNB:7_h_M;=BS‏
996 ‎‡2 RERO|A000138286‏
996 ‎‡2 LC|no2002050003‏
996 ‎‡2 ISNI|0000000392182798‏
996 ‎‡2 DNB|128712546‏
996 ‎‡2 SUDOC|084107812‏
996 ‎‡2 BNF|12179634‏
996 ‎‡2 BNF|11922209‏
996 ‎‡2 DNB|1118763750‏
996 ‎‡2 LC|nb2010018690‏
996 ‎‡2 DNB|1136590382‏
996 ‎‡2 NUKAT|n 99068005‏
996 ‎‡2 SUDOC|281201412‏
996 ‎‡2 LC|n 79016371‏
996 ‎‡2 SUDOC|265749301‏
996 ‎‡2 BIBSYS|90127093‏
996 ‎‡2 BNF|15584387‏
996 ‎‡2 LC|n 94061298‏
996 ‎‡2 NKC|xx0122324‏
996 ‎‡2 LC|n 84000657‏
996 ‎‡2 ICCU|TO0V026889‏
996 ‎‡2 ISNI|0000000028452560‏
996 ‎‡2 NII|DA06980896‏
996 ‎‡2 SZ|1137564989‏
996 ‎‡2 LC|nr 90018976‏
996 ‎‡2 LC|n 90724744‏
996 ‎‡2 ERRR|12469920‏
996 ‎‡2 CAOONL|ncf10956529‏
996 ‎‡2 DNB|122967380‏
996 ‎‡2 NII|DA08473833‏
996 ‎‡2 CAOONL|ncf10716398‏
996 ‎‡2 BNE|XX1151032‏
996 ‎‡2 LC|n 79020863‏
996 ‎‡2 PLWABN|9810548384805606‏
996 ‎‡2 ISNI|0000000062737949‏
996 ‎‡2 SUDOC|067643108‏
996 ‎‡2 LC|no 99029416‏
996 ‎‡2 DNB|1318570565‏
996 ‎‡2 BIBSYS|90627766‏
996 ‎‡2 LC|nb2005006927‏
996 ‎‡2 ISNI|0000000030722662‏
996 ‎‡2 LC|n 2011016565‏
996 ‎‡2 N6I|vtls000330907‏
996 ‎‡2 LC|no2017138427‏
996 ‎‡2 LC|n 95075605‏
996 ‎‡2 ISNI|0000000442631986‏
996 ‎‡2 LC|n 91124659‏
996 ‎‡2 LC|nb2010017868‏
996 ‎‡2 ISNI|000000004602392X‏
996 ‎‡2 ISNI|0000000109353011‏
996 ‎‡2 NYNYRILM|201675‏
996 ‎‡2 NKC|uk2007334957‏
996 ‎‡2 ISNI|0000000044436106‏
996 ‎‡2 BAV|495_303996‏
996 ‎‡2 ISNI|0000000499954735‏
996 ‎‡2 LC|n 88030491‏
996 ‎‡2 DNB|118091085‏
996 ‎‡2 LC|n 2008023116‏
996 ‎‡2 NUKAT|n 2004095588‏
996 ‎‡2 ISNI|0000000029296985‏
996 ‎‡2 LC|n 96108573‏
996 ‎‡2 CAOONL|ncf11449641‏
996 ‎‡2 SUDOC|235091995‏
996 ‎‡2 LNB|LNC10-000118039‏
996 ‎‡2 RERO|A006083406‏
996 ‎‡2 SELIBR|252801‏
996 ‎‡2 ISNI|0000000114633851‏
996 ‎‡2 CAOONL|ncf10309943‏
996 ‎‡2 ISNI|000000008665980X‏
996 ‎‡2 BIBSYS|3042040‏
996 ‎‡2 DNB|172989191‏
996 ‎‡2 DNB|107470147X‏
996 ‎‡2 LC|no 99020426‏
996 ‎‡2 NUKAT|n 2004073836‏
996 ‎‡2 NUKAT|n 00056638‏
996 ‎‡2 J9U|987007463394305171‏
996 ‎‡2 BIBSYS|3000551‏
996 ‎‡2 LC|no2021138409‏
996 ‎‡2 ISNI|0000000420512177‏
996 ‎‡2 LC|nb2010020764‏
996 ‎‡2 NUKAT|n 94303288‏
996 ‎‡2 NTA|153142820‏
996 ‎‡2 RERO|A022960233‏
996 ‎‡2 NUKAT|n 2004050413‏
996 ‎‡2 PLWABN|9810555922905606‏
996 ‎‡2 NTA|22975113X‏
996 ‎‡2 LC|n 2016064627‏
996 ‎‡2 ISNI|0000000108452376‏
996 ‎‡2 LC|nr 89007990‏
996 ‎‡2 NKC|mzk20191058032‏
996 ‎‡2 LC|no2016014200‏
996 ‎‡2 ISNI|0000000082121308‏
996 ‎‡2 ISNI|0000000451168081‏
996 ‎‡2 ISNI|0000000021570169‏
996 ‎‡2 ISNI|0000000031633119‏
996 ‎‡2 NUKAT|n 02724778‏
996 ‎‡2 LC|no2003039438‏
996 ‎‡2 NKC|jx20111212040‏
996 ‎‡2 LC|n 93002777‏
996 ‎‡2 SUDOC|272956317‏
996 ‎‡2 LC|n 87824415‏
996 ‎‡2 NYNYRILM|46584‏
996 ‎‡2 ISNI|0000000108556845‏
996 ‎‡2 ISNI|0000000086701713‏
996 ‎‡2 NII|DA16106805‏
996 ‎‡2 BIBSYS|90545430‏
996 ‎‡2 NUKAT|n 2013194397‏
996 ‎‡2 LNB|LNC10-000189708‏
996 ‎‡2 LC|n 87929826‏
996 ‎‡2 BIBSYS|3115568‏
996 ‎‡2 DNB|1147222959‏
996 ‎‡2 LC|n 85133016‏
996 ‎‡2 LNB|LNC10-000189706‏
996 ‎‡2 LNB|LNC10-000189707‏
996 ‎‡2 DNB|1089306148‏
996 ‎‡2 NTA|073728888‏
996 ‎‡2 LC|n 86053683‏
996 ‎‡2 NTA|067862837‏
996 ‎‡2 JPG|500069454‏
996 ‎‡2 ISNI|0000000115067679‏
996 ‎‡2 NTA|069187630‏
996 ‎‡2 BNF|12367830‏
996 ‎‡2 PLWABN|9810688941505606‏
996 ‎‡2 DBC|87097947558948‏
996 ‎‡2 NKC|jx20110824021‏
996 ‎‡2 ISNI|0000000084449198‏
996 ‎‡2 DNB|142134864‏
996 ‎‡2 BNE|XX826814‏
996 ‎‡2 LC|n 92097298‏
996 ‎‡2 LC|nb2023004251‏
996 ‎‡2 RERO|A003751269‏
996 ‎‡2 RERO|A003751268‏
996 ‎‡2 LIH|LNB:V-347479;=BU‏
996 ‎‡2 ISNI|0000000389719654‏
996 ‎‡2 BIBSYS|90181832‏
996 ‎‡2 LC|no2014038298‏
996 ‎‡2 RERO|A003751263‏
996 ‎‡2 RERO|A003751262‏
996 ‎‡2 RERO|A003751261‏
996 ‎‡2 B2Q|0001441515‏
996 ‎‡2 RERO|A003751267‏
996 ‎‡2 RERO|A003751266‏
996 ‎‡2 LC|nr 93033457‏
996 ‎‡2 RERO|A003751264‏
996 ‎‡2 ISNI|0000000030317595‏
996 ‎‡2 J9U|987007267169405171‏
996 ‎‡2 J9U|987007307139205171‏
996 ‎‡2 LC|no2007156702‏
996 ‎‡2 LC|nb2015002013‏
996 ‎‡2 NLA|000035455424‏
996 ‎‡2 ISNI|0000000039650108‏
996 ‎‡2 ISNI|0000000041916251‏
996 ‎‡2 DNB|1037701895‏
996 ‎‡2 PLWABN|9810600036005606‏
996 ‎‡2 BNE|XX943827‏
996 ‎‡2 LC|no2020088750‏
996 ‎‡2 ISNI|0000000034344275‏
996 ‎‡2 ISNI|0000000082771538‏
996 ‎‡2 LC|no2013001184‏
996 ‎‡2 DNB|172523923‏
996 ‎‡2 RERO|A018529360‏
996 ‎‡2 SUDOC|087654466‏
996 ‎‡2 LC|n 80068385‏
996 ‎‡2 LC|no2014074271‏
996 ‎‡2 ISNI|0000000457391153‏
996 ‎‡2 ISNI|0000000035205912‏
996 ‎‡2 LC|n 84028081‏
996 ‎‡2 BIBSYS|90670693‏
996 ‎‡2 SELIBR|261604‏
996 ‎‡2 ISNI|0000000049873794‏
996 ‎‡2 LC|nr 93033455‏
996 ‎‡2 LC|n 94042124‏
996 ‎‡2 BIBSYS|90611580‏
996 ‎‡2 ISNI|0000000042740112‏
996 ‎‡2 LC|no2016020040‏
996 ‎‡2 LNB|LNC10-000055710‏
996 ‎‡2 CAOONL|ncf11570523‏
996 ‎‡2 LC|nr 93015069‏
996 ‎‡2 DNB|142130486‏
996 ‎‡2 LC|no2009053300‏
996 ‎‡2 DNB|138763496‏
996 ‎‡2 RERO|A027080969‏
996 ‎‡2 SUDOC|262806290‏
996 ‎‡2 J9U|987007573242405171‏
996 ‎‡2 LC|nb2004012950‏
996 ‎‡2 LC|n 88619939‏
996 ‎‡2 DNB|121325016‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏